Valbiotis: Invest Securities confirms its rating after CMD

(CercleFinance.com) - Invest Securities confirms its buy rating on Valbiotis shares, with an unchanged target price of 3 euros.


The analyst reports that Valbiotis unveiled "ambitious prospects for 2030" at its CMD (investor day), which he considers "not unrealistic" but "very aggressive".

We understand that the company's objective is to replicate the success of Pharmanutra on the French market", notes Invest Securities, which points out that it has made several changes following this CMD, namely: (i) an increase in sales assumptions to levels that remain below target, (ii) a lowering of margins to the upper end of the target range, and (iii) an increase in cash consumption.

According to our assumptions, additional financing could be considered in 2026", adds the analyst.


Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.